USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary Of Significant Accounting Policies (Tables)

Summary Of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 29, 2018

Summary Of Significant Accounting Policies [Abstract]

Schedule Of Assets And Liabilities Measured At Fair Value



		Fair Value Measurements Using
		Inputs
	December 30, 2017	Level 1	Level 2	Level 3

Money market funds included in cash equivalents	$ 106,090	$ 106,090	$ -	$ -
Foreign currency contracts included in other current liabilities	(139)	-	(139)	-

	$ 105,951	$ 106,090	$ (139)	$ -

		Fair Value Measurements Using
		Inputs
	December 29, 2018	Level 1	Level 2	Level 3

Money market funds included in cash equivalents	$ 129,449	$ 129,449	$ -	$ -
Foreign currency contracts included in other current liabilities	(309)	-	(309)	-

	$ 129,140	$ 129,449	$ (309)	$ -

Schedule Of Contract Liabilities From Contract With Customers


		As of
		December 29,
		2018

Contract liabilities at beginning of period		$ 14,417
Increase due to deferral of revenue at period end		15,055
Decrease due to beginning contract liabilities recognized as revenue		(14,417)

Contract liabilities at end of period		$ 15,055

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details